MeSH term
Frequency | Condition_Probility | Female | 86 | 0.0 |
Humans | 395 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Apoptosis/immunology | 2 | 2.0 |
Cell Communication/immunology | 2 | 2.0 |
Cell Cycle/immunology | 3 | 9.0 |
Cell Division | 26 | 0.0 |
Cell Line | 40 | 0.0 |
Coculture Techniques | 16 | 2.0 |
Lymphocyte Activation/*immunology | 8 | 1.0 |
Male | 88 | 0.0 |
Receptors, Interleukin-2/*metabolism | 3 | 4.0 |
Research Support, Non-U.S. Gov't | 255 | 0.0 |
T-Lymphocytes/*immunology | 25 | 1.0 |
Antigens, CD58/metabolism | 12 | 75.0 |
*Apoptosis | 3 | 0.0 |
Cytokines/*biosynthesis | 7 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Intercellular Adhesion Molecule-1/*metabolism | 4 | 7.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Up-Regulation | 16 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Transfection | 28 | 0.0 |
Adult | 73 | 0.0 |
*Cell Adhesion | 6 | 3.0 |
Immunohistochemistry | 13 | 0.0 |
Middle Aged | 63 | 0.0 |
Phenotype | 26 | 0.0 |
Biological Markers | 7 | 0.0 |
Caco-2 Cells | 2 | 0.0 |
Down-Regulation | 4 | 0.0 |
Leukocytes, Mononuclear/cytology/immunology | 2 | 4.0 |
Lymphocytes/*immunology | 7 | 1.0 |
Monocytes/*immunology | 4 | 0.0 |
Time Factors | 12 | 0.0 |
Aged | 42 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Antigens, CD/analysis | 35 | 2.0 |
Chromosome Aberrations | 2 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Genes, myc | 3 | 1.0 |
HLA-DR Antigens/analysis | 6 | 0.0 |
Immunophenotyping | 46 | 1.0 |
Karyotyping | 8 | 0.0 |
Receptors, Antigen, T-Cell/analysis | 3 | 2.0 |
Rats | 17 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 69 | 0.0 |
Amino Acid Sequence | 27 | 0.0 |
Animals | 82 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 3 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Molecular Sequence Data | 42 | 0.0 |
Phosphorylation | 4 | 0.0 |
Protein Binding | 7 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
In Vitro | 30 | 0.0 |
Ionophores/pharmacology | 2 | 1.0 |
Cell Line, Transformed | 10 | 0.0 |
Cell Separation | 13 | 1.0 |
DNA Primers/chemistry | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Lymphocyte Activation | 48 | 1.0 |
T-Lymphocytes/physiology | 4 | 3.0 |
Antigens, CD58/*genetics | 3 | 75.0 |
Antigens, CD59/*genetics | 2 | 20.0 |
Base Sequence | 21 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Introns | 2 | 0.0 |
Killer Cells, Natural/immunology | 7 | 1.0 |
Models, Biological | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
T-Lymphocytes/immunology | 27 | 1.0 |
Antigen Presentation/immunology | 2 | 2.0 |
Antigens, CD/metabolism | 19 | 2.0 |
Cell Adhesion | 29 | 2.0 |
Comparative Study | 39 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Killer Cells, Lymphokine-Activated/immunology | 4 | 6.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Tumor Cells, Cultured | 57 | 0.0 |
Antibodies, Monoclonal/immunology | 15 | 0.0 |
Antigens, CD/*physiology | 8 | 2.0 |
Antigens, CD18/physiology | 2 | 16.0 |
Antigens, CD2/physiology | 3 | 12.0 |
Antigens, CD58/physiology | 3 | 42.0 |
Cell Division/physiology | 3 | 0.0 |
Cells, Cultured | 71 | 0.0 |
Flow Cytometry | 65 | 1.0 |
Intercellular Adhesion Molecule-1/physiology | 2 | 8.0 |
Interferon Type II/physiology | 2 | 2.0 |
Statistics, Nonparametric | 2 | 0.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Antigens, CD14/analysis | 6 | 5.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Cell Communication | 5 | 1.0 |
Clone Cells/pathology | 2 | 3.0 |
Fetal Blood/cytology | 2 | 1.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 12 | 1.0 |
Blotting, Northern | 6 | 0.0 |
Erythrocytes/immunology | 7 | 2.0 |
*Gene Expression | 2 | 0.0 |
Lung/immunology | 2 | 6.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Rosette Formation | 13 | 4.0 |
Sheep | 7 | 1.0 |
Cytokines/biosynthesis | 6 | 1.0 |
Gene Expression | 10 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Interferon Type II/biosynthesis | 7 | 1.0 |
Ligands | 23 | 0.0 |
*Lymphocyte Activation | 20 | 1.0 |
Macaca mulatta | 2 | 0.0 |
United States | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 4 | 4.0 |
Acute Disease | 7 | 0.0 |
Adolescent | 18 | 0.0 |
Antigens, CD/*metabolism | 14 | 2.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Cell Adhesion Molecules/*metabolism | 14 | 5.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 3 | 6.0 |
Multivariate Analysis | 4 | 0.0 |
Prognosis | 7 | 0.0 |
Survival Rate | 5 | 0.0 |
Antigen Presentation | 8 | 2.0 |
Fetal Blood/*cytology | 5 | 2.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Hematopoietic Stem Cell Mobilization | 2 | 2.0 |
Lymphocyte Culture Test, Mixed | 16 | 2.0 |
Monocytes/*cytology | 2 | 2.0 |
Killer Cells, Natural/*immunology | 14 | 2.0 |
Lymphocyte Subsets/*immunology | 3 | 2.0 |
Antigens, CD58/*immunology/*metabolism | 2 | 100.0 |
Cell Adhesion/drug effects | 4 | 0.0 |
Interferon Type II/pharmacology | 13 | 2.0 |
Jurkat Cells | 8 | 0.0 |
Phytohemagglutinins/pharmacology | 7 | 1.0 |
Protein Binding/drug effects | 2 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 8 | 0.0 |
Antibodies, Monoclonal | 25 | 1.0 |
English Abstract | 6 | 0.0 |
Binding Sites | 16 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Electrostatics | 2 | 1.0 |
Hydrogen Bonding | 2 | 1.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Models, Molecular | 13 | 0.0 |
Mutation | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Structure-Activity Relationship | 6 | 0.0 |
Antigens, CD2/*physiology | 2 | 8.0 |
Antigens, CD80/physiology | 3 | 9.0 |
B-Lymphocytes/immunology | 5 | 0.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
L Cells (Cell Line) | 3 | 1.0 |
Lymphokines/secretion | 2 | 5.0 |
Mice | 40 | 0.0 |
Recombinant Proteins/pharmacology | 9 | 0.0 |
Epitopes | 7 | 0.0 |
Molecular Structure | 2 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
*Cell Line | 4 | 8.0 |
Collagen/metabolism | 2 | 0.0 |
Mice, SCID | 5 | 0.0 |
Organ Specificity | 4 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 6 | 1.0 |
Blotting, Western | 7 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
Glycosylation | 9 | 0.0 |
Point Mutation | 3 | 0.0 |
Protein Conformation | 13 | 0.0 |
*Signal Transduction | 4 | 0.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Antigens, CD58/genetics/*immunology | 2 | 100.0 |
Antigens, CD58/immunology | 4 | 57.0 |
Epitope Mapping | 2 | 0.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Lymphocyte Subsets | 2 | 1.0 |
Cell Lineage | 2 | 0.0 |
Child | 12 | 0.0 |
Child, Preschool | 9 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
*Gene Expression Regulation, Leukemic | 2 | 2.0 |
Infant | 8 | 0.0 |
Neoplasm, Residual | 2 | 2.0 |
Remission Induction | 2 | 0.0 |
Skin Tests | 2 | 1.0 |
Lymphocyte Activation/drug effects | 7 | 1.0 |
*Nuclear Proteins | 2 | 0.0 |
Antigens, CD29/analysis | 2 | 9.0 |
Antigens, CD40/analysis | 2 | 8.0 |
Antigens, CD44/analysis | 3 | 4.0 |
Antigens, CD58/analysis | 5 | 45.0 |
Cell Adhesion Molecules/*analysis/genetics | 2 | 18.0 |
Cell Transformation, Viral | 2 | 0.0 |
Cytokines/pharmacology | 8 | 2.0 |
Gene Expression Regulation | 3 | 0.0 |
Histocompatibility Antigens Class I/analysis | 4 | 4.0 |
Intercellular Adhesion Molecule-1/analysis | 4 | 3.0 |
Interleukin-4/pharmacology | 6 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Cell Culture Techniques | 2 | 0.0 |
Antigens, CD/immunology | 13 | 2.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Interferon Type II/secretion | 2 | 1.0 |
Membrane Glycoproteins/*immunology | 5 | 2.0 |
Receptors, Immunologic/immunology | 4 | 3.0 |
Antigens, CD/analysis/immunology | 2 | 4.0 |
Leukemia, Myeloid/*immunology/pathology | 2 | 14.0 |
Myelodysplastic Syndromes/immunology/pathology | 2 | 66.0 |
Membrane Glycoproteins/*physiology | 8 | 3.0 |
Adjuvants, Immunologic/*pharmacology | 5 | 3.0 |
Histocompatibility Antigens Class II/analysis | 3 | 1.0 |
Membrane Glycoproteins/analysis | 6 | 2.0 |
Antigens, CD2/immunology/metabolism | 2 | 66.0 |
Antigens, CD28/physiology | 2 | 2.0 |
Antigens, CD58/*physiology | 5 | 71.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Lymphocyte Activation/immunology | 7 | 1.0 |
Mice, Inbred DBA | 2 | 0.0 |
Signal Transduction/immunology | 3 | 0.0 |
Cell Membrane/immunology | 3 | 1.0 |
Hematopoietic Stem Cells/immunology | 2 | 2.0 |
Antigen-Presenting Cells/*immunology | 7 | 4.0 |
Antigens, Surface/immunology | 5 | 2.0 |
Autoantigens/immunology | 2 | 1.0 |
Cytotoxicity, Immunologic | 16 | 1.0 |
Macrophages/immunology | 3 | 1.0 |
T-Lymphocyte Subsets/immunology | 4 | 1.0 |
T-Lymphocytes, Cytotoxic/immunology | 6 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 4 | 2.0 |
Solubility | 12 | 0.0 |
Antigens, CD/biosynthesis | 8 | 2.0 |
Apoptosis | 2 | 0.0 |
CD40 Ligand | 5 | 2.0 |
Cell Adhesion Molecules/metabolism | 16 | 6.0 |
Fibroblasts | 2 | 0.0 |
HLA-DR Antigens/biosynthesis | 3 | 3.0 |
Membrane Glycoproteins/metabolism | 6 | 1.0 |
Cell Differentiation | 22 | 0.0 |
Dendritic Cells/drug effects/*immunology | 2 | 7.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Antigens, CD80/metabolism | 3 | 3.0 |
Platelet Activating Factor/pharmacology | 2 | 4.0 |
Antigens, CD/*genetics | 3 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Antigens, CD58/*analysis | 3 | 100.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Antigens, CD/*biosynthesis | 5 | 2.0 |
Epitopes/immunology | 3 | 0.0 |
Lipopolysaccharides/*pharmacology | 3 | 0.0 |
Monocytes/drug effects/*immunology | 2 | 2.0 |
Immunosuppressive Agents/*pharmacology | 3 | 1.0 |
Cell Membrane/immunology/metabolism | 2 | 1.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Cell Adhesion Molecules/*analysis | 14 | 11.0 |
Integrin alpha4 | 3 | 7.0 |
Integrins/analysis | 4 | 8.0 |
Reference Values | 8 | 0.0 |
Antigens, CD95/*immunology | 2 | 5.0 |
Apoptosis/*immunology | 3 | 1.0 |
*Cytotoxicity, Immunologic | 11 | 2.0 |
Antigens, CD58/biosynthesis | 2 | 28.0 |
HLA-DR Antigens/*biosynthesis | 2 | 6.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 2 | 9.0 |
Membrane Glycoproteins/biosynthesis | 3 | 1.0 |
Antigens, CD/*immunology | 7 | 1.0 |
Antigens, CD2/*immunology | 2 | 5.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Antigens, CD58/chemistry/metabolism | 2 | 100.0 |
Cell Adhesion/*physiology | 3 | 2.0 |
Cell Line, Tumor | 2 | 0.0 |
*Protein Structure, Secondary | 5 | 3.0 |
Sequence Alignment | 4 | 0.0 |
Antigens, CD/biosynthesis/*immunology | 2 | 10.0 |
*Immunotherapy, Adoptive | 2 | 3.0 |
Antigens, CD2/*chemistry/metabolism | 4 | 66.0 |
Antigens, CD58/*chemistry/metabolism | 2 | 100.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Interleukin-2/pharmacology | 12 | 2.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
In Situ Hybridization | 2 | 0.0 |
Microscopy, Electron | 5 | 0.0 |
*Antigens, CD | 5 | 0.0 |
Antigens, CD40/immunology | 4 | 7.0 |
Antigens, CD80/immunology | 2 | 3.0 |
Cell Division/drug effects | 3 | 0.0 |
Histocompatibility Antigens Class I/biosynthesis | 4 | 8.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
Tumor Stem Cells/cytology/*drug effects/metabolism | 2 | 100.0 |
Cell Count | 2 | 0.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
Immunomagnetic Separation | 3 | 2.0 |
*Immunophenotyping | 2 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 10 | 1.0 |
Clone Cells | 8 | 0.0 |
Cytotoxicity Tests, Immunologic | 7 | 1.0 |
T-Lymphocytes, Cytotoxic/*immunology | 7 | 1.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Antigens, CD18/metabolism | 4 | 8.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Killer Cells, Natural/drug effects/*immunology | 2 | 5.0 |
Dendritic Cells/*physiology | 6 | 7.0 |
Fluorescent Antibody Technique | 10 | 0.0 |
*Antigen Presentation | 5 | 3.0 |
Antigens, CD/physiology | 8 | 3.0 |
Antigens, CD95/*physiology | 2 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 5 | 1.0 |
Membrane Glycoproteins/physiology | 5 | 3.0 |
HLA-D Antigens/*immunology | 3 | 5.0 |
T-Lymphocytes/drug effects/*immunology | 4 | 2.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
Integrins/metabolism | 3 | 1.0 |
Cell Adhesion Molecules/analysis | 11 | 7.0 |
Cell Membrane/metabolism | 3 | 0.0 |
K562 Cells | 2 | 0.0 |
Receptors, Very Late Antigen/metabolism | 2 | 18.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Molecular Weight | 5 | 0.0 |
B-Lymphocytes/cytology/*immunology | 2 | 2.0 |
Enterotoxins/immunology | 2 | 3.0 |
Superantigens/immunology | 3 | 6.0 |
Crystallography, X-Ray | 3 | 0.0 |
Cell Division/immunology | 5 | 1.0 |
Antigens, CD2/chemistry/metabolism | 2 | 66.0 |
Escherichia coli/genetics | 2 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Immunotherapy | 4 | 1.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Antigens, CD/immunology/*metabolism | 2 | 4.0 |
Binding, Competitive | 6 | 0.0 |
Membrane Glycoproteins/immunology/*metabolism | 2 | 4.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Antigens, CD | 3 | 2.0 |
Antigens, Differentiation/analysis | 5 | 1.0 |
Infant, Newborn | 3 | 0.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
Antigens, CD34 | 6 | 0.0 |
Antigens, Differentiation | 2 | 2.0 |
Cell Adhesion Molecules/*biosynthesis | 7 | 7.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Swine | 2 | 0.0 |
Dendritic Cells/*immunology | 5 | 2.0 |
Membrane Glycoproteins/immunology | 7 | 3.0 |
Case-Control Studies | 2 | 0.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Stimulation, Chemical | 3 | 0.0 |
Blast Crisis | 2 | 5.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Leukemia, Myelocytic, Acute/immunology/pathology | 2 | 28.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Antigens, CD45/analysis | 5 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 4 | 1.0 |
Antigens, CD2/metabolism | 6 | 21.0 |
Protein Binding/genetics/immunology | 2 | 2.0 |
Staining and Labeling | 3 | 0.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Monocytes/*cytology/*immunology | 2 | 50.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Killer Cells, Lymphokine-Activated/*immunology | 10 | 14.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Enterotoxins/pharmacology | 2 | 3.0 |
Intercellular Adhesion Molecule-1/immunology | 2 | 4.0 |
Antibodies | 2 | 0.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
Disease-Free Survival | 2 | 0.0 |
Antigens, CD58/immunology/*metabolism | 3 | 100.0 |
Cell Cycle | 4 | 0.0 |
DNA/metabolism | 3 | 0.0 |
*Protein Conformation | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 1.0 |
Receptors, Immunologic/*physiology | 6 | 3.0 |
Antigens, CD58/*metabolism | 4 | 66.0 |
Antigens, CD58/biosynthesis/immunology | 2 | 66.0 |
Intercellular Adhesion Molecule-1/biosynthesis/immunology | 2 | 40.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Intercellular Adhesion Molecule-1/*analysis | 2 | 10.0 |
Melanoma/immunology/pathology/*therapy | 2 | 33.0 |
Antigens, CD2/immunology | 2 | 6.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Bone Marrow/*pathology | 3 | 2.0 |
*Hematopoiesis | 2 | 1.0 |
Survival Analysis | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 2 | 2.0 |
B-Lymphocytes/*immunology | 4 | 0.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
Temperature | 4 | 0.0 |
Antigens, CD29/*biosynthesis | 2 | 50.0 |
Cell Adhesion Molecules/biosynthesis | 6 | 7.0 |
Antigens, CD/*analysis | 15 | 1.0 |
HLA-DR Antigens/*analysis | 3 | 1.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Cell Adhesion Molecules/physiology | 4 | 4.0 |
HL-60 Cells | 2 | 0.0 |
Tumor Stem Cells/*immunology | 2 | 8.0 |
Transcription, Genetic | 4 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 5 | 0.0 |
Cytokines/metabolism | 3 | 0.0 |
Immunoglobulin E/*biosynthesis | 2 | 4.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
Antigens, CD3/analysis | 2 | 0.0 |
Cell Adhesion/immunology | 9 | 5.0 |
Cell Adhesion Molecules/*immunology | 5 | 9.0 |
Integrin alpha4beta1 | 2 | 2.0 |
Receptors, Lymphocyte Homing/analysis | 6 | 18.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
Cell Movement | 10 | 1.0 |
Antigens, CD2/*metabolism | 5 | 15.0 |
Kinetics | 11 | 0.0 |
Antibodies, Monoclonal/*pharmacology | 3 | 1.0 |
Chromatography, Affinity | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
*Immune Tolerance | 2 | 1.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Antigens, CD58/immunology/metabolism | 3 | 75.0 |
Antigens, Surface/biosynthesis | 2 | 3.0 |
Enterotoxins/*immunology | 2 | 2.0 |
Intercellular Adhesion Molecule-1/immunology/metabolism | 4 | 44.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Antigens, CD1/analysis | 3 | 3.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Signal Transduction | 7 | 0.0 |
Antibodies, Monoclonal/chemistry/pharmacology | 2 | 40.0 |
Antigens, CD44/physiology | 2 | 9.0 |
Hamsters | 12 | 0.0 |
Immunoglobulins/chemistry | 2 | 8.0 |
Epithelium/immunology/pathology | 2 | 7.0 |
HLA Antigens/analysis | 3 | 1.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Immunoglobulin G/metabolism | 3 | 1.0 |
Antigens, CD11/metabolism | 2 | 10.0 |
*HIV-1 | 3 | 0.0 |
Receptors, IgE/metabolism | 2 | 6.0 |
Tonsil/cytology | 2 | 2.0 |
Mice, Inbred C3H | 2 | 0.0 |
Antigens, CD58/*blood | 3 | 100.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Erythrocytes/metabolism | 2 | 1.0 |
T-Lymphocyte Subsets/*immunology | 7 | 1.0 |
*Ultraviolet Rays | 2 | 0.0 |
Antigens, CD/*immunology/metabolism | 2 | 6.0 |
Antigens, Surface/*immunology | 2 | 1.0 |
Cell Aggregation/immunology | 2 | 10.0 |
Hybridomas | 3 | 2.0 |
CHO Cells | 9 | 0.0 |
Drug Synergism | 4 | 0.0 |
Immunotherapy/*methods | 3 | 2.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Neoplasms/*immunology/*therapy | 2 | 14.0 |
Dendritic Cells/*cytology/*immunology | 2 | 13.0 |
Transplantation, Heterologous | 3 | 0.0 |
Erythrocytes/*immunology | 4 | 2.0 |
Lymphocytes/immunology/*metabolism | 2 | 8.0 |
Cell Adhesion Molecules/*physiology | 11 | 9.0 |
Cytokines/physiology | 2 | 1.0 |
Extracellular Matrix/metabolism | 2 | 1.0 |
Multigene Family | 2 | 0.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Antigens, CD45/*metabolism | 2 | 6.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Receptors, Antigen, T-Cell/*metabolism | 2 | 1.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
Antigens, CD45/*immunology | 2 | 6.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 2 | 3.0 |
Interleukin-4/biosynthesis | 2 | 1.0 |
Antigens, CD/biosynthesis/genetics | 2 | 5.0 |
Intercellular Adhesion Molecule-1/*physiology | 3 | 18.0 |
Binding, Competitive/immunology | 6 | 6.0 |
Blood Sedimentation | 2 | 1.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Multiple Myeloma/*metabolism | 2 | 7.0 |
Dendritic Cells/*cytology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*physiology | 2 | 0.0 |
Membrane Glycoproteins/*metabolism | 8 | 1.0 |
Receptors, Immunologic/*metabolism | 5 | 2.0 |
Cohort Studies | 2 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Cell Movement/immunology | 2 | 2.0 |
Endothelium, Vascular/metabolism | 3 | 1.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Glycosylphosphatidylinositols/*metabolism | 2 | 3.0 |
Hemoglobinuria, Paroxysmal/*blood | 2 | 7.0 |
Monocytes/metabolism | 2 | 0.0 |
Antigens, CD2/*chemistry | 2 | 50.0 |
Cell Aggregation | 3 | 2.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 3 | 6.0 |
Monocytes/*physiology | 2 | 1.0 |
Bone Marrow Cells | 2 | 0.0 |
Carbohydrate Sequence | 4 | 1.0 |
Epitopes/chemistry | 2 | 2.0 |
Intestinal Mucosa/cytology/*immunology | 2 | 13.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Monocytes/cytology | 2 | 1.0 |
Anemia, Aplastic/complications | 2 | 50.0 |
Erythrocytes/chemistry | 2 | 4.0 |
Glycosylphosphatidylinositols/*blood | 2 | 28.0 |
Immune Tolerance | 4 | 1.0 |
Interleukin-1/*physiology | 2 | 2.0 |
T-Lymphocytes/*physiology | 3 | 1.0 |
Receptors, Interleukin-2/analysis | 4 | 1.0 |
Common Cold/epidemiology/*immunology | 2 | 100.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Binding Sites, Antibody | 2 | 0.0 |
Cell Communication/*immunology | 2 | 4.0 |
T-Lymphocytes/immunology/metabolism | 2 | 1.0 |
Antigens, Neoplasm/metabolism | 2 | 2.0 |
Lymphocytes, Tumor-Infiltrating/drug effects/immunology | 2 | 66.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Receptors, Lymphocyte Homing/biosynthesis | 2 | 11.0 |
Langerhans Cells/*immunology | 2 | 5.0 |
Langerhans Cells/*metabolism | 2 | 10.0 |
Antibody Specificity | 2 | 0.0 |
Cell Adhesion Molecules/analysis/biosynthesis | 2 | 40.0 |
Major Histocompatibility Complex | 3 | 1.0 |
Antigens, CD58 | 68 | 46.0 |
T-Lymphocytes/*drug effects/immunology | 2 | 2.0 |
*Antigens, Differentiation | 2 | 2.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Antigens, CD55 | 3 | 1.0 |
Antigens, CD59 | 8 | 4.0 |
Antigens, Surface/*biosynthesis | 3 | 12.0 |
Antigen-Presenting Cells/*physiology | 2 | 5.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Antigens, CD40 | 4 | 7.0 |
Antigens, CD80/immunology/metabolism | 2 | 22.0 |
Up-Regulation/immunology | 2 | 1.0 |
Cytotoxicity, Immunologic/*drug effects | 3 | 4.0 |
Apoptosis/physiology | 2 | 0.0 |
Inositol Phosphates/metabolism | 2 | 1.0 |
Antigens, CD18 | 9 | 9.0 |
Integrins/*analysis | 4 | 16.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 4 | 9.0 |
Macromolecular Substances | 4 | 0.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Interleukin-2/biosynthesis | 5 | 1.0 |
Isoantigens/immunology | 3 | 3.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Membrane Glycoproteins/biosynthesis/genetics | 2 | 4.0 |
Interleukin-6/*physiology | 2 | 2.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Antigens, Surface/*genetics | 2 | 3.0 |
Cell Adhesion/physiology | 3 | 1.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
Thymus Gland/*immunology | 2 | 3.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*physiology | 2 | 5.0 |
Antigens, CD2 | 43 | 9.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 6 | 2.0 |
Receptors, Immunologic/*immunology | 6 | 5.0 |
Leukocytes/*physiology | 2 | 3.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 4 | 9.0 |
Protein Folding | 4 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 3 | 1.0 |
Antigens, CD/*blood | 2 | 1.0 |
Culture Media | 2 | 0.0 |
Intercellular Adhesion Molecule-1 | 36 | 15.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 5 | 6.0 |
Receptors, Immunologic/physiology | 6 | 5.0 |
Integrins/*metabolism | 3 | 2.0 |
Bacteria/*immunology | 2 | 11.0 |
Liver/*immunology | 2 | 5.0 |
Lymphocyte Subsets/immunology | 2 | 1.0 |
Cell Adhesion/*immunology | 2 | 10.0 |
Antigens, CD11 | 8 | 9.0 |
Antigens, CD8/analysis | 2 | 0.0 |
Antigens, CD44 | 2 | 1.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Receptors, Immunologic/analysis | 5 | 5.0 |
Cell Adhesion Molecules/immunology | 2 | 2.0 |
HLA Antigens/*immunology | 2 | 0.0 |
Multiple Sclerosis/*immunology | 2 | 1.0 |
Immunoblotting | 5 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 5 | 4.0 |
Interleukin-2/*physiology | 2 | 2.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
Hybridomas/immunology | 2 | 1.0 |
Oligonucleotide Probes | 2 | 0.0 |
Antigens, CD/analysis/*metabolism | 2 | 13.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Epstein-Barr Virus Nuclear Antigens | 4 | 9.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*metabolism | 2 | 25.0 |
*Immunologic Memory | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 4 | 1.0 |
Receptors, Immunologic/*analysis | 2 | 3.0 |
Monocytes/immunology | 3 | 0.0 |
Immunity, Cellular | 6 | 0.0 |
Cell Adhesion Molecules/*analysis/physiology | 3 | 33.0 |
Leukemia, T-Cell/*immunology | 2 | 11.0 |
Burkitt Lymphoma/immunology | 3 | 16.0 |
Immunization | 2 | 0.0 |
Receptors, Antigen, T-Cell/*physiology | 4 | 2.0 |
Antigens, CD29 | 4 | 6.0 |
Membrane Glycoproteins/*analysis | 8 | 5.0 |
Antigens, CD28 | 4 | 2.0 |
Antigens, CD3/physiology | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 7 | 4.0 |
Immunologic Memory | 3 | 1.0 |
Leukocyte Count | 3 | 0.0 |
Antigens, CD45 | 7 | 3.0 |
Antigens, Viral/genetics | 2 | 11.0 |
Leukocytes, Mononuclear/pathology | 2 | 10.0 |
Lymphocyte Function-Associated Antigen-1/*analysis | 2 | 25.0 |
Antigens, Surface/analysis | 3 | 0.0 |
Phagocytosis | 2 | 0.0 |
Antigens, Surface/*metabolism | 4 | 6.0 |
Antigens, CD3 | 5 | 1.0 |
Antigens, Surface/*physiology | 4 | 6.0 |
Antigens, CD80 | 2 | 6.0 |
Recombinant Proteins | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Glycosylphosphatidylinositols | 3 | 5.0 |
Histocompatibility Antigens/analysis | 5 | 8.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Receptors, Leukocyte-Adhesion/*analysis | 4 | 44.0 |
Antigens, Surface/*analysis | 5 | 2.0 |
Neoplasm Transplantation | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1 | 3 | 3.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Antigens, Surface/physiology | 2 | 5.0 |
Antigen-Presenting Cells/immunology | 3 | 1.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Receptors, Lymphocyte Homing/*analysis | 2 | 5.0 |
Cytochalasin B/pharmacology | 2 | 2.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Antigens, Differentiation/*analysis | 3 | 1.0 |
Lymphocyte Function-Associated Antigen-1 | 2 | 2.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Leukapheresis | 2 | 1.0 |
